icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
J. Hou,1 H. Ma,2 J. Sun,1 Q. Xie,3 Y. Xie,4 Y. Sun,5 H. Wang,6 G. Shi,7 M. Wan,8 J. Niu,9 Q. Ning,10 Y. Yu,11 Y. Zhao12
1Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2Liver Research Center, Beijing Friendship Hospital, Beijing, China; 3Department of Infectious Disease, Shanghai Ruijin Hospital, Shanghai, China; 4Liver Disease Department, Beijing DiTan Hospital, Beijing, China; 5Department of Infectious Disease, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; 6Liver Disease Department, Peking University People's Hospital, Beijing, China; 7Department of Infectious Disease, Huashan Hospital affiliated to Fudan University, Shanghai, China; 8Department of Infectious Disease, Shanghai Changhi Hospital, Shanghai, China; 9Department of Liver, First Hospital of Jilin University, Changchun, China; 10Department of Infectious Disease, Wuhan Tongji Hospital affiliated to Huazhong Technology University, Tongji Medical College, Wuhan, China; 11Department of Infectious Disease, Peking University First Hospital, Beijing, China; 12Shanghai Roche Pharmaceuticals Co. Ltd, Shanghai, China